Analytical Data
-
Gene name
Apolipoprotein L/APOL1
- Application
-
Alternative Names
Apo-L; APOL; APOL-I
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O14791
-
Expression Region
Met1~Trp15+Val34~Ala238
-
Molecular Weight
56kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein L1 (APOL1) is a key protein involved in lipid metabolism and has gained significant attention due to its role in kidney diseases, particularly in individuals of African descent. Genetic variants of APOL1 have been linked to an increased risk of focal segmental glomerulosclerosis (FSGS) and hypertension-attributed kidney disease. The presence of APOL1 risk alleles influences the susceptibility to kidney injury and is thought to provide a selective advantage against certain infections, such as sleeping sickness caused by Trypanosoma brucei. Research into recombinant APOL1 proteins has emerged as a crucial approach to elucidate their functional roles, interaction mechanisms, and the molecular pathways implicated in kidney disease. By expressing and purifying recombinant APOL1 proteins, scientists aim to study the biochemical properties and investigate how variants of this protein affect cellular functions and contribute to the pathogenesis of renal disorders. This research not only enhances our understanding of APOL1's physiological roles but also has potential therapeutic implications for developing targeted interventions for kidney diseases associated with APOL1 genetic variants. Understanding the intricate relationship between APOL1 and renal health could lead to novel strategies for prevention and treatment, ultimately improving outcomes for genetically predisposed populations.
